Bioatla Inc
BCAB
NASDAQ
Biotechnology
$3.09
USD
-0.36 (-10.43%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $5.73M
Volume 143.7K
Revenue
$2.00M
TTM
-81.8%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-50.62M
TTM
+18.2%
YoY
Operating Cash Flow
$-37.18M
TTM
+35.2%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 2.0 | 0.0 |
YoY Growth | — | — | -100.0% | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 2.0 | 0.0 |
Selling, General & Administrative | 5.3 | 5.0 | 4.3 | 3.3 | 4.7 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 17.6 | 18.6 | 13.8 | 11.3 | 9.3 |
Operating Income | -17.6 | -18.6 | -13.8 | -9.3 | -9.3 |
EBITDA | -17.4 | -18.5 | -13.7 | -9.2 | -9.2 |
Other Income / Expense | 1.9 | -0.3 | -2.1 | -0.6 | 2.9 |
Total Other Income / Expense | 2.3 | -0.1 | -2.0 | -0.5 | 3.0 |
Income Before Income Taxes | -15.3 | -18.7 | -15.8 | -9.8 | -6.3 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -15.3 | -18.7 | -15.8 | -9.8 | -6.3 |
Consolidated Net Income / Loss | -15.3 | -18.7 | -15.8 | -9.8 | -6.3 |
Net Income Attributable to Common Shareholders | -15.3 | -18.7 | -15.8 | -9.8 | -6.3 |
Basic EPS | -$13.16 | -$16.00 | -$13.50 | -$8.18 | -$4.22 |
Diluted EPS | -$13.16 | -$16.00 | -$13.50 | -$8.18 | -$4.22 |
Basic Shares Outstanding | 1.2M | 1.2M | 1.2M | 1.2M | 1.5M |
Diluted Shares Outstanding | 1.2M | 1.2M | 1.2M | 1.2M | 1.5M |